News about "chronic weight management "

Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity

Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity

Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.

Chronic Weight Management | 21/03/2026 | By News Bureau 443

Novo Nordisk Wins FDA Approval for Wegovy HD to Advance Obesity Treatment

Novo Nordisk Wins FDA Approval for Wegovy HD to Advance Obesity Treatment

FDA approves Novo Nordisk’s Wegovy HD (semaglutide 7.2 mg), a higher-dose weekly injection delivering significant weight loss, supported by strong Phase III trial outcomes.

Chronic Weight Management | 21/03/2026 | By News Bureau 119

Sun Pharma Wins DCGI Nod for Generic Semaglutide Injection

Sun Pharma Wins DCGI Nod for Generic Semaglutide Injection

Sun Pharmaceutical has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic semaglutide injection for chronic weight management, paving the way for its entry into the fast-growing obesity treatment segment once the semaglutide patent expires in the country.

Chronic Weight Management | 27/01/2026 | By News Bureau 186

Novo Nordisk Files for FDA Approval of Wegovy Injection 7.2 mg

Novo Nordisk Files for FDA Approval of Wegovy Injection 7.2 mg

Novo Nordisk has filed an sNDA with the US FDA for a 7.2 mg dose of Wegovy, aiming to offer a higher-dose option for adults with obesity. The application, supported by STEP UP trial data showing 20.7 percent average weight loss, will be reviewed under the FDA’s expedited CNPV pathway.

Chronic Weight Management | 29/11/2025 | By Dineshwori 342

Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India

Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India

Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.

Chronic Weight Management | 10/11/2025 | By Dineshwori 735


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members